Mrs Lindsay Marie Hixon, PT, DPT | |
4100 Lake Otis Pkwy Ste 108, Anchorage, AK 99508-5230 | |
(907) 563-3145 | |
(833) 464-5196 |
Full Name | Mrs Lindsay Marie Hixon |
---|---|
Gender | Female |
Speciality | Physical Therapy |
Experience | 11 Years |
Location | 4100 Lake Otis Pkwy Ste 108, Anchorage, Alaska |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356739791 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | PT28521 (Florida) | Secondary |
225100000X | Physical Therapist | 2704 (Alaska) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Medical Network Of Alaska Llc | 3072618859 | 61 |
News Archive
The Sohn Conference Foundation today unveiled the Sohn Collaborative for Liquid Biopsy at Weill Cornell Medicine to develop a blood test that will predict how cancer spreads in both children and adults.
UT Southwestern Medical Center researchers have found that a naturally occurring protein - transforming growth factor beta1 (TGF-1) - which normally suppresses the growth of cancer cells, causes a rebound effect after a prolonged exposure.
Coeliac disease is a typical example of a malabsorption syndrome conferring increased risk for various deficiency states, including folate and vitamin B12.
Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.
› Verified 2 days ago
Provider Name | Anchorage Fracture And Orthopaedic Clinic Pc |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1285677054 PECOS PAC ID: 7517914187 Enrollment ID: O20050405001438 |
News Archive
The Sohn Conference Foundation today unveiled the Sohn Collaborative for Liquid Biopsy at Weill Cornell Medicine to develop a blood test that will predict how cancer spreads in both children and adults.
UT Southwestern Medical Center researchers have found that a naturally occurring protein - transforming growth factor beta1 (TGF-1) - which normally suppresses the growth of cancer cells, causes a rebound effect after a prolonged exposure.
Coeliac disease is a typical example of a malabsorption syndrome conferring increased risk for various deficiency states, including folate and vitamin B12.
Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.
› Verified 2 days ago
Provider Name | Medical Network Of Alaska Llc |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1538414834 PECOS PAC ID: 3072618859 Enrollment ID: O20070424000329 |
News Archive
The Sohn Conference Foundation today unveiled the Sohn Collaborative for Liquid Biopsy at Weill Cornell Medicine to develop a blood test that will predict how cancer spreads in both children and adults.
UT Southwestern Medical Center researchers have found that a naturally occurring protein - transforming growth factor beta1 (TGF-1) - which normally suppresses the growth of cancer cells, causes a rebound effect after a prolonged exposure.
Coeliac disease is a typical example of a malabsorption syndrome conferring increased risk for various deficiency states, including folate and vitamin B12.
Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.
› Verified 2 days ago
Mailing Address | Practice Location Address |
---|---|
Mrs Lindsay Marie Hixon, PT, DPT 4100 Lake Otis Pkwy Ste 108, Anchorage, AK 99508-5230 Ph: (907) 563-3145 | Mrs Lindsay Marie Hixon, PT, DPT 4100 Lake Otis Pkwy Ste 108, Anchorage, AK 99508-5230 Ph: (907) 563-3145 |
News Archive
The Sohn Conference Foundation today unveiled the Sohn Collaborative for Liquid Biopsy at Weill Cornell Medicine to develop a blood test that will predict how cancer spreads in both children and adults.
UT Southwestern Medical Center researchers have found that a naturally occurring protein - transforming growth factor beta1 (TGF-1) - which normally suppresses the growth of cancer cells, causes a rebound effect after a prolonged exposure.
Coeliac disease is a typical example of a malabsorption syndrome conferring increased risk for various deficiency states, including folate and vitamin B12.
Peregrine Pharmaceuticals, Inc. (PPHM) today reported publication of data in the online edition of the journal Current Cancer Therapy Reviews that supports the clinical potential of the company's novel brain cancer agent Cotara® for the treatment of patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara specifically targets cells at the center of brain tumors, so its radioactive payload is able to kill cancer cells while leaving healthy tissue largely unaffected. Cotara is currently being tested in a Phase II clinical trial in recurrent GBM patients.
› Verified 2 days ago
Katrina F Johnson, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4315 Diplomacy Dr, Anchorage, AK 99508 Phone: 907-563-2662 | |
Jessie Lief, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4031 Winchester Loop, Anchorage, AK 99507 Phone: 907-244-8048 | |
Zoe Anneliese Morris Nelson, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1917 Abbott Rd Ste 200, Anchorage, AK 99507 Phone: 907-279-4266 | |
Normajean Farr, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 2221 E Northern Lights Blvd, Suite 106, Anchorage, AK 99508 Phone: 907-677-5605 | |
Mary Beth Nearing, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 602 W 42nd Ave, Anchorage, AK 99503 Phone: 907-360-9448 Fax: 907-346-1470 | |
Kids Are People Too Llc Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6311 Debarr Rd, Suite J, Anchorage, AK 99504 Phone: 907-830-3592 Fax: 907-338-4691 | |
Ms. Catherine A Coward, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 9500 Independence Dr, Ste 900, Anchorage, AK 99507 Phone: 907-522-1341 Fax: 907-522-1343 |